Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: Subanalyses of ADEPT

Journal of Rheumatology

Volumn 40, Issue 5, 2013, Pages 647-652

  Mease, Philip J ^a,b   Heckaman, Michele ^c   Kary, Sonja ^c   Kupper, Hartmut ^c  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c ABBVIE INC   (United States)

Author keywords

Adalimumab; Psoriatic arthritis; Severity of illness index

Indexed keywords

ADALIMUMAB; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE;

ADULT; ARTHROPATHY; ARTICLE; BODY SURFACE; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERMETHOD COMPARISON; JOINT SWELLING; JOINT TENDERNESS; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; MINIMAL DISEASE ACTIVITY; PAIN ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; PSORIASIS ARTHRITIS SEVERITY INDEX; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADALIMUMAB; PSORIATIC ARTHRITIS; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; MIDDLE AGED; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 84876906761     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120970     Document Type: Article

References (27)

1. Mease PJ. Psoriatic arthritis: Update on pathophysiology, assessment and management. Ann Rheum Dis 2011;70 Suppl 1:i77-84.
2. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64. (Pubitemid 351509657)
3. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
4. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36. (Pubitemid 40530131)
5. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
6. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
7. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
8. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, Fitzgerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: Current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012;71:319-26.
9. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
10. Mease PJ. Measures of psoriatic arthritis. Arthritis Care Res 2011;63:S64-S85.
11. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
12. Helliwell PS, Fitzgerald O, Strand CV, Mease PJ. Composite measures in psoriatic arthritis: A report from the GRAPPA 2009 annual meeting. J Rheumatol 2011;38:540-5.
13. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
14. Tugwell P, Boers M, Brooks P, Simon L, Strand V, Idzerda L. OMERACT: An international initiative to improve outcome measurement in rheumatology. Trials 2007;8:38.
15. Coates LC, Cook R, Lee KA, Chandran V, Gladman DD. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res 2010;62:970-6.
16. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res 2010;62:965-9.
17. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii65-8; discussion ii9-73.
18. Robinson A, Kardos M, Kimball AB. Physician global assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol 2012;66:369-75.
19. Gottlieb AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area and Severity Index (PASI) and physician's global assessment (PGA): A comparison. J Drugs Dermatol 2003;2:260-6.
20. Fredriksson T, Pettersson U. Severe psoriasis - Oral therapy with a new retinoid. Dermatologica 1978;157:238-44. (Pubitemid 8387357)
21. Faria JR, Aarao AR, Jimenez LM, Silva OH, Avelleira JC. Inter-rater concordance study of the PASI (Psoriasis Area and Severity Index). An Bras Dermatol 2010;85:625-9.
22. Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: The impact of area should be increased. Br J Dermatol 2004;151:381-7. (Pubitemid 39215151)
23. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005;32:2262-9. (Pubitemid 41587879)
24. van de Kerkhof PC, Kragballe K, Austad J, Berth-Jones J, Cambazard F, de la Brassinne M, et al. Psoriasis: Severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity. Eur J Dermatol 2006;16:167-71.
25. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systematic review. J Invest Dermatol 2010;130:933-43.
26. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum 2008;59:686-91. (Pubitemid 351679544)
27. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszynski WP, Wong RL, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009;68:948-53.